Palazestrant
Fulvestrant
Olema Pharmaceuticals, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Fulvestrant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT Olema Pharmaceuticals, Inc. | Phase 1 | CC |
op-3136 Olema Pharmaceuticals, Inc. | Phase 1 | CC |
Palbociclib Tianjin Medical University Cancer Institute and Hospital | D |
Same molecule, other indications
Palazestrant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →